Crisaborole Powder

After more than ten years of development, the company has established close cooperative relations with many domestic chemical research institutions and has a number of production bases. Production in strict accordance with ISO, GMP,FDA standards, products through strict factory testing, to ensure 100% qualified products.

What is Crisaborole powder?

Crisaborole powder is a medication that is used topically to treat mild-to-moderate eczema in adults and children two years and older. It works by reducing inflammation and itching in the affected areas of the skin.
Eczema, also called atopic dermatitis, is a common skin condition that causes red, itchy, and sometimes blistering rashes. It is usually treated with emollients, corticosteroids, or immunomodulators. However, some patients may not respond well to these treatments or may experience side effects, leading to a need for alternative medications.

Crisaborole powder was developed as an alternative treatment for eczema that is safe and effective with minimal side effects. The active ingredient in crisaborole powder is the boron compound, which helps to reduce inflammation by inhibiting the production of certain inflammatory cytokines.
How to use Crisaborole powder?
To use crisaborole powder, the affected area of skin should be cleaned and dried before applying a thin layer of the medication. The powder should be spread evenly over the affected area, and gently rubbed into the skin until it is absorbed. The medication should be applied twice daily, once in the morning and once in the evening.

Crisaborole powder application:
Crisaborole powder has been shown to be effective in reducing the severity of eczema symptoms, including itching, redness, and inflammation. Additionally, it has been found to be safe with few side effects. Side effects that have been reported include burning or stinging at the site of application, which typically resolves quickly and does not require discontinuation of treatment.

In clinical trials, crisaborole powder was found to be more effective than a placebo in reducing eczema symptoms. Additionally, patients reported improved quality of life and satisfaction with the treatment.

Crisaborole powder is a promising treatment option for patients with mild-to-moderate eczema who may not respond well to other treatments or who may experience side effects from corticosteroids or immunomodulators. It is safe and effective with minimal side effects, and has been shown to improve the quality of life of patients with eczema.

In conclusion, crisaborole powder is a new and effective treatment option for those suffering from eczema. It is safe, easy to use and comfortable, with minimal side effects. With the dramatic improvement in the quality of life enjoyed by many patients who have used this powder, it is clear that Crisaborole powder is a valuable option in the fight against eczema.

4-[(1,3-Dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrileAN2728;AN-2728,>=98%;AN2728,Crisaborole;Crisaborole(AN2728);AN2728;AN2728/ANChemicalbook-2728;4-((1-Hydroxy-1,3-dihydrobenzo-[c][1,2]oxaborol-5-yl)oxy)benzonitrile;4-[(1,3-Dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile

Introduction
Criborole (AN2728) is a non-steroidal phosphodiesterase 4 (PDE-4) inhibitor. It was first developed by Anacor Pharmaceuticals. In May 2016, Pfizer acquired A Chemical booknacor. In December of the same year, the US FDA approved Criborole (AN2728) ointment (2% or 5%) for local treatment of mild For moderate to moderate atopic dermatitis, the trade name is Eucrisa.

Introduction
Criborole (AN2728) is a non-steroidal phosphodiesterase 4 (PDE-4) inhibitor. It was first developed by Anacor Pharmaceuticals. In May 2016, Pfizer acquired A Chemical booknacor. In December of the same year, the US FDA approved Criborole (AN2728) ointment (2% or 5%) for local treatment of mild For moderate to moderate atopic dermatitis, the trade name is Eucrisa.

Product advantages
The biggest advantage of Criborole is that it is a small-molecule non-hormonal drug that can achieve both therapeutic effect and comfort, and even has almost no side effects for some patients. It is the first dermatology topical drug that entered the list of new Chemicalbook drugs that are urgently needed in clinical practice. It can be said that the launch of crisborole has filled the treatment needs of children and adults with atopic dermatitis in China, breaking the current situation of no new products in the field of topical non-hormonal anti-inflammatory for more than 10 years, which is of epoch-making significance.

market outlook
Cripborole was developed by Anacor, and Pfizer acquired Anacor at a high price. In December 2016, Cripborole was approved by the US FDA for marketing, becoming the first new drug approved by the US FDA for the treatment of atopic dermatitis (AD) in the past 15 years. molecular entity. In July 2020, Criborole Ointment was approved for marketing in China, becoming the first and only hormone-free PDE-4 inhibitor topical in China for children and adults aged 2 years and above to treat mild to moderate atopic dermatitis prescription. Criborole is a phosphodiesterase 4 (PDE4) inhibitor. PDE4 is an enzyme involved in controlling the activity of inflammatory cells. PDE4 Chemicalbook participates in IL-4/5 in inflammatory cells by controlling the degradation of cyclic adenosine monophosphate. The production of inflammatory factors such as /10/13 and prostaglandin PGE2 plays a role by inhibiting the activity of PDE4 to improve the body's inflammatory response. Clinical studies have shown that in patients with mild to moderate atopic dermatitis aged 2-79 years, compared with placebo, crisborole treatment for 28 days can lead to significant remission and complete or almost complete resolution of the rash. In 2017, the sales of crisborole was US$67 million; in 2018, the global sales of crisborole was US$147 million, with a growth rate of 119.40%, which brought new hope to many patients with atopic dermatitis.

use
AN2728 has shown potent activity both in vivo and in vitro, and the anti-inflammatory properties of AN2728 are being investigated. Also used as pharmaceutical intermediates.
biological activity
Crisaborole (AN2728) is a selective small molecule PDE4 inhibitor with broad-spectrum anti-inflammatory activity. target

Hot Tags: crisaborole powder, China, suppliers, manufacturers, factory, wholesale, buy, bulk, price, for sale, in stock, Disodium Creatine Phosphate Tetrahydrate, Pure Lidocaine Powder, Creatine Phosphate Disodium, Terbinafine HCl Powder, Standard Ozenoxacin Powder, Bisoprolol Fumarate Powder